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Stevens–Johnson syndrome (SJS) is a severe mucocutaneous adverse drug reaction with a relatively high mortality rate. SJS is
described during herpes simplex virus type 1 (HSV1) infection and, rarely, even during adalimumab therapy.We report the case of
a patient with Crohn’s disease who developed SJS during an HSV1 infection and a contemporaneous anti-TNFα therapy with
adalimumab. Remission was achieved with suspension of adalimumab and high doses of intravenous steroids and antivirals.
Patients with HSV1 infection and on adalimumab therapy have a combined risk of SJS and should be monitored closely.
1. Introduction
Stevens–Johnson syndrome (SJS) is a severe mucocutaneous
adverse reaction, characterized by necrosis of skin and
mucosa upper layers, with consequent formation of vesicles,
bullae, and ulcers. In SJS, skin detachment involves less than
10% of the body surface area [1]. Common initial clinical
manifestations of SJS are malaise, fatigue, persistent high
fever, skin tenderness, and pain. In SJS, the primary im-
munological barrier of the skin is disrupted and there is an
increased risk of infections [2, 3]. SJS is considered a severe
drug reaction, as drugs are its most common trigger [4, 5]. It
is a medical condition that usually requires hospitalization
and that has a mortality rate of 1–5% [6].
We describe the case of an IBD patient who developed
SJS during a herpes simplex type 1 infection and a con-
temporary anti-TNF alpha therapy with adalimumab.
2. Case Report
A 44-year-old female patient was diagnosed with ileocolonic
steno-penetrating Crohn’s disease in 2006. She also suffered
from dermatological manifestations of the disease (erythema
nodosum and psoriasiform dermatitis). Initially, the patient
was treated with systemic steroids and mesalamine and
achieved a good clinical response. Subsequently, mesalamine
was interrupted due to drug intolerance. In 2007, the disease
flared up, so the patient underwent an ileocolonic resection.
No postoperative treatment was initiated. 'e patient was
first referred to our Inflammatory Bowel Disease Center
(AOU Careggi, Florence) in 2015 because of a disease re-
lapse. In order to assess disease activity, a colonoscopy,
abdomen CTscan, and digestive MRI scan were carried out,
which revealed a 8–10-cm long preanastomotic stricture.
'us, in October 2015, the patient started treatment with
adalimumab. After three months of therapy, the patient was
admitted to our hospital with malaise, high fever, pain,
pruritus, and skin and mucosa detachment of <5% of body
surface area (mouth, periorbital region, palms, and soles)
with positive Nikolsky sign; (Figures 1 and 2) she also
presented with vesicular lesions of the nostrils and nasolabial
fold. 'e patient underwent a vesicle swab, which demon-
strated the presence of HSV1 DNA. 'e patient was eval-
uated by our consultant Dermatologist and was diagnosed
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with herpes simplex type 1 infection complicated by bac-
terial superinfection with impetigo and SJS. Isolation pre-
cautions were used because of the patient’s high risk of
acquiring infection. 'e patient was treated with fluids,
antivirals, and high doses of intravenous steroids until she
achieved complete remission. 'is event could either have
been a consequence of the herpes simplex type 1 infection, or
an adverse reaction to adalimumab, therefore, in this
eventuality, the treatment was discontinued. Nevertheless,
we decided to start treatment with infliximab in December
2017, after consulting our Immunologist who confirmed the
absence of contraindications to the treatment with a dif-
ferent anti-TNF alpha drug. She is currently still being
treated with infliximab and regularly attends follow-up visits
at our Outpatient Department. She has not developed any
adverse events to the drug.
3. Discussion
Skin reactions to adalimumab are frequent and extremely
varied. 'e most common dermatologic adverse event to
adalimumab is injection-site erythema and pruritus, which
resolve spontaneously and occur less frequently with time.
Conversely, eczema and psoriasiform lesions can be so se-
vere as to cause treatment interruption [7].
In the literature, only two other cases of SJS during
adalimumab therapy are described: Mounach et al. pre-
sented the case of a 53-year-old patient who was treated with
adalimumab for rheumatoid arthritis [8], while Salama and
Lawrance described the case of a 29-year-old patient with
ileocolonic steno-penetrating Crohn’s disease, with der-
matological and rheumatological extraintestinal manifesta-
tions [9].
In both these cases, the clinical manifestations were
pathognomonic, with peripheral rash, abdominal skin de-
tachment, and oral cavity mucositis, so that biopsy was not
necessary for diagnosis. In both these cases, as well as in our,
SJS resolved with the suspension of adalimumab and with
the administration of high doses of intravenous steroids; the
patients were then switched to infliximab therapy without
complications [8, 9].
On the other hand, herpes simplex type 1 infection is also
a well-known cause of SJS and one of the most frequent
triggers of erythema multiforme [10, 11]. In 1992, Detjen
et al. described a case of SJS in a 36-year-old man with
recurrent HSV-related oropharyngitis; even in this case, as
in ours, the patient was treated with antivirals and steroids,
achieving complete resolution of signs and symptoms [12].
4. Conclusions
SJS is a severe medical condition, described during HSV type
1 infection and, rarely, even during adalimumab therapy.
Patients in treatment with biologic drugs, such as ada-
limumab, are more susceptible to recurrent reactivation of
HSV type 1 infection. As a result, they have a combined risk
of SJS. Patients who are treated with adalimumab should be
monitored closely, especially in case of simultaneous therapy
with other drugs, and should be advised to seek immediate
medical care if alarming symptoms appear.
Conflicts of Interest
'e authors declare that they have no conflicts of interest.
References
[1] E.-J. Kim, H. Lim, S. Y. Park et al., “Rapid onset of Stevens-
Johnson syndrome and toxic epidermal necrolysis after in-
gestion of acetaminophen,” Asia Pacific Allergy, vol. 4, no. 1,
pp. 68–72, 2014.
[2] R. P. Dodiuk-Gad, W.-H. Chung, L. Valeyrie-Allanore, and
N. H. Shear, “Stevens-Johnson syndrome and toxic epidermal
necrolysis: an update,” American Journal of Clinical Derma-
tology, vol. 16, no. 6, pp. 475–493, 2015.
[3] F. A. Pereira, A. V. Mudgil, and D. M. Rosmarin, “Toxic
epidermal necrolysis,” Journal of the American Academy of
Dermatology, vol. 56, no. 2, pp. 181–200, 2007.
[4] S. Anne, S. Kosanam, and L. N. Prasanthi, “Steven Johnson
syndrome and toxic epidermal necrolysis: a review,” Inter-
national Journal of Pharmaceutical Research, vol. 4, pp. 158–
165, 2014.
[5] L. E. French, “Toxic epidermal necrolysis and Stevens Johnson
syndrome: our current understanding,” Allergology Interna-
tional, vol. 55, no. 1, pp. 9–16, 2006.
[6] T. Harr and L. E. French, “Toxic epidermal necrolysis and
Stevens-Johnson syndrome,” Orphanet Journal of Rare Dis-
eases, vol. 5, no. 1, p. 39, 2010.
[7] C. Hillemand and R. Leong, “Gastrointestinal: cutaneous
reaction associated with loss of response to adalimumab,”
Figure 1: Perioral desquamative lesions.
Figure 2: Palmar desquamative lesions.
2 Case Reports in Gastrointestinal Medicine
Journal of Gastroenterology and Hepatology, vol. 28, no. 7,
p. 1073, 2013.
[8] A. Mounach, A. Rezqi, A. Nouijai et al., “Stevens-Johnson
syndrome complicating adalimumab therapy in rheumatoid
arthritis disease,” Rheumatology International, vol. 33, no. 5,
pp. 1351–1353, 2013.
[9] M. Salama and I. C. Lawrance, “Stevens-Johnson syndrome
complicating adalimumab therapy in Crohn’s disease,”World
Journal of Gastroenterology, vol. 15, no. 35, pp. 4449–4452,
2009.
[10] W. B. Shelly, “Herpes simplex virus as a cause of erythema
multiforme,” JAMA, vol. 201, pp. 153–156, 1967.
[11] P. W. Orton, J. C. Huff, M. G. Tonnesen, and W. L. Weston,
“Detection of a herpes simplex viral antigen in skin lesions of
erythema multiforme,” Annals of Internal Medicine, vol. 101,
no. 1, pp. 48–50, 1984.
[12] P. F. Detjen, R. Patterson, G. A. Noskin, J. P. Phair, and
S. O. Loyd, “Herpes simplex virus associated with recurrent
Stevens-Johnson syndrome,” Archives of Internal Medicine,
vol. 152, no. 7, pp. 1513–1516, 1992.
Case Reports in Gastrointestinal Medicine 3
